Rogue Venture Partners, whose largest limited partner is Oregon State University, has led a $3.7m funding round for Lensabl.

Researchers at University of Alabama at Birmingham will be able to apply for up to $35,000 in funding to support the commercialisation of their inventions.

SEI Ventures will invest in seed-stage companies and give startups the opportunity to pilot their technologies across Strayer University and Capella University.

Neil Sharkey, vice-president for research at Penn State University, will retire on June 30, with a national search for a replacement launching immediately.

Arch Venture Partners has filed to raise its largest fund to date that would increase assets under management by the venture capital firm to $2.86bn.

Quark Venture and GF Securities have invested $1.9m in Sitka Biopharma, a spinout of University of British Columbia and Centre for Drug Research and Development.

The VPRI Innovation Fund will invest between $25,000 and $75,000 at the proof-of-concept stage to drive commercialisation activities at University of Oregon.

Ohio Innovation Fund has returned to support a first series B tranche for Enable Injections, which is targeting a $50m final close.

Stanford-StartX Fund's portfolio company Gauss Surgical has received series C funding from SoftBank and eight healthcare providers.

Fosun Pharma has committed series A funding to Glycotest, a liver disease diagnostics developer based on research at Baruch S. Blumberg Institute and Drexel University.